Transcept Pharmaceuticals to Present at the Susquehanna Financial Group's SIGnificant Investment Options in Healthcare ... ( PT. RICHMOND Calif. Feb. 19 /- Tr...)

HOME >> MEDICINE >> NEWS

Transcept Pharmaceuticals to Present at the Susquehanna Financial Group's SIGnificant Investment Options in Healthcare Conference

Date:2/19/2008

PT. RICHMOND, Calif., Feb. 19 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, Chief Executive Officer & President, will present at the Susquehanna Financial Group's Second Annual SIGnificant Investment Options in Healthcare Conference at the W Hotel, 541 Lexington Avenue, in New York City on Tuesday, March 4, 2008 at 8:30 AM Eastern Time.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product candidate, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept plans to submit an NDA in the third quarter of 2008. Another product being developed by Transcept is TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. For further information, please visit the company's website at: http://www.transcept.com.

Contacts:

Transcept Pharmaceuticals, Inc. The Ruth Group

Michael Gill Investors / Media

Director of Communications Stephanie Carrington / Jason Rando

(510) 215-3575 (646) 536-7017 / 7025

mgill@transcept.com scarrington@theruthgroup.com

jrando@theru
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
4. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
8. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
9. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
10. NUCRYST Pharmaceuticals announces year-end results
11. Renhuang Pharmaceuticals, Inc. Retains CCG Elite

Post Your Comments:

(Date:11/23/2009)...ATBORO,Pa.,Nov.23/PRNewswire-FirstCall/--InfoLogix...nterprisemobilitysolutionsforthehealthcareandcomme...ePresidentofManagedServicesatSiemensHealthServices...hcareServices. ,, (Logo: http://www.newscom.com...residentofStrategicHealthcareServicesforInfoLogix,...

(Date:11/23/2009)...uarters of cancer patients and survivors treated w...s that often become chronic conditions, hindering ...cientists at the University of Rochester Medical C...hey experienced sleep troubles at nearly three tim... was more prevalent in younger patients and those ...

(Date:11/23/2009)...es saw their odds drop by 63 percent with moderate...Nov. 23 (HealthDay News) -- Moderate-to-high inten...may help reduce stroke risk in older men but not i...ed almost 3,300 men and women, average age 69, in ...During that time, there were 238 strokes among the...

(Date:11/23/2009)...nts up weaknesses of drug approval process in Unit...ov. 23 (HealthDay News) -- Problems with the popul...for heart attack, stroke and death, were known for... the market in 2004, a new report says. , Cont...., dangerous side effects were evident in 2000, a ...

(Date:11/23/2009)... SayscuttingMedicaretofinance"reform"isamoraloutra.../--WhiletheSenateDemocratsmovedforwardtobeginthede...eSafe,a400,000supporterstronggrassrootssenioradvoc...irbullhornstoprotestthemassivecutstoMedicare.Retir...gthefocusshifttoissuesliketaxes,abortion,andimmigr...

Breaking Medicine News(10 mins):Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 2 Health News:Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services 3 Health News:Insomnia prevalent among cancer patients who receive chemotherapy 2 Health News:Vigorous Exercise Cuts Stroke Risk for Men, Not Women 2 Health News: Vioxx Problems Known Years Before Recall 2 Health News: Vioxx Problems Known Years Before Recall 3 Health News: Vioxx Problems Known Years Before Recall 4 Health News:RetireSafe Calls on Seniors to Grab their Bullhorns to Save Medicare from Rationed Care 2

[0] Jim Way, Former Vice President at Siemens Health Services, Joins InfoLogix, Inc. as Vice President of Strategic Healthcare Services [0] Insomnia prevalent among cancer patients who receive chemotherapy [1] Vigorous Exercise Cuts Stroke Risk for Men, Not Women [0] Vioxx Problems Known Years Before Recall [1] RetireSafe Calls on Seniors to Grab their Bullhorns to Save Medicare from Rationed Care

...s available in Spanish . , The autistic disord... by Dr. Leo Kanner of the Johns Hopkins Hospital (...tism. At the same time an Austrian scientist, Dr. ...rmal language function. Today, both disorders are ...

...usan G. Komen for the Cure(R), the,leader of the g...ization,the Susan G. Komen for the Cure Advocacy A...ttendees of the Republican National Convention,abo...com.com/cgi-bin/prnh/20070122/NYM084LOGO ), Komen...

...ncer Chronicles Film Festival awards prizes to top..., Sept. 1 Chrigu from Switzerland has been,awarde...ncer Chronicles,Film Festival at a ceremony in Gen...Story, The Children of Avenir (Morocco),for Best O...

...Aug. 31 Elbit Imaging Ltd.,(Nasdaq: EMITF ) ("EI...r the,second quarter of 2008., Profit for the sec...approximately US$ 16.7 million) of which profit of...llion) is,attributable to minority interest, compa...

.... - The fight against the liver disease hepatitis ...ith more than 150 million people currently infecte...sty side effects and often falling short of a cure...cess that in lab testing could be effectively targ...

...l but significant reduction in deaths; parallel st...cial effect. , , SUNDAY, Aug. 31 (HealthDa...rated fatty acids -- the kind found in fish oil --...effect in a parallel heart failure trial. , "This ...

The first autism disease genes Komen Travels to Republican Convention to Raise Awareness of Breast Cancer Issues Chrigu Wins Grand Prize at First Ever International Documentary Film Festival on Cancer Elbit Imaging Ltd. Announces Second Quarter Results for 2008 New approach, old drug show promise against hepatitis C, Stanford research shows Fish Oil Supplements Help With Heart Failure

(Date:11/23/2009)...exas,Nov.23/PRNewswire-FirstCall/--WoundManagement...rowingproviderofspecialtymedicalproducts,announced...edacomprehensivemanagementbusinessupdatetoillustra... Q32009salesincreased33.5%to$102,926vs.Q32008sales...creasedto$3,327,892vs.Q32008shareholderequityof$(3...

(Date:11/23/2009)...S,Nov.23/PRNewswire/--AMDLASERSannouncedthisweekth...ionbypartneringwithprestigiousindustry-leaderDr.La...ERS,willbetheexclusivesofttissuediodelaserusedduri...rgetedtothetop2%ofdentists. ,, (Photo: http://w..., "ItiswithgreatpleasurethatIproudlyannounceourpa...

(Date:11/23/2009)...NCISCO,Calif.,Nov.23/PRNewswire-FirstCall/--Anesiv...eandDr.DavidC.U,PrichardhaveagreedtojointheAnesiva...rgerbetweenAnesivaandArcionTherapeutics.Completion...akeplaceatthepreviouslyannouncedAnesiva2009AnnualM...0a.m.PSTat400OysterPoint,Suite107A,SouthSanFrancis...

Breaking Medicine Technology:Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2 Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3 Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4 Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5 AMD LASERS Announces New Partnership with Dr. Larry Rosenthal and Aesthetic Advantage 2 Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2 Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3 Colorado Companies Team Up With U S Fish 26amp 3B Wildlife Service to Protect Black Footed Ferret 14744 1 Colorado Companies Team Up With U S Fish 26amp 3B Wildlife Service to Protect Black Footed Ferret 14744 2 Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 1 Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 2 Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 3 Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 4 Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 5 Helix BioPharma Corp Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha 2b in Patients With Ano Genital Warts 6036 6 Federal stimulus funds support studies geared to improving HIV care and prevention 60794 1 Federal stimulus funds support studies geared to improving HIV care and prevention 60794 2

[0] Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update [0] AMD LASERS Announces New Partnership with Dr. Larry Rosenthal and Aesthetic Advantage [0] Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger

... Shows R84, the Selective Human Anti-VEGF Antibod...fitech, Is Equivalent to Avastin in Inhibiting Gro...ical Breast Cancer Model -- -- R84 Is Being Ad...ON and TUSTIN, Calif., Nov. 13 Peregrine,Pharmace...opharmaceutical,company developing targeted monocl...

...AX) today reported financial results for the third... recent accomplishments and upcoming,milestones. N... equivalent,of $0.15 loss per share, compared with...08 loss per share in the third quarter of 2006. F...ompany reported a,net loss of $25.5 million or $0....

Other Medicine Technology:New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 2 New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 3 New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 4 New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models 5 Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 2 Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 3 Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 4 Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 5 Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 6

New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs

Sugita Aneurysm Clip J-Shaped (M)

Sugita Aneurysm Clip 1/4 Cvd. (L)

Sugita Aneurysm Clip 45 Angled (L)

Sugita Aneurysm Clip L-Shaped (S)

Medicine Products:

Sugita Aneurysm Clip J-Shaped (M)Sugita Aneurysm Clip 1/4 Cvd. (L)Sugita Aneurysm Clip 45 Angled (L)Sugita Aneurysm Clip L-Shaped (S)

Transcept Pharmaceuticals to Present at the Susquehanna Financial Group's SIGnificant Investment Options in Healthcare ...( PT. RICHMOND Calif. Feb. 19 /- Tr...),Health